Core Viewpoint - Company shares of Basilea Pharmaceutica (02616) rose over 3%, currently trading at 6.99 HKD with a transaction volume of 15.38 million HKD, following the announcement of key clinical data to be presented at the upcoming ESMO conference in October 2025 [1] Group 1: Clinical Pipeline Updates - Basilea announced that its core clinical pipeline, CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody), will present preliminary data from an ongoing Phase I dose-escalation study at the ESMO conference [1] - The abstract for CS2009 includes data from 9 patients as of the submission deadline on May 8, 2025, aimed at meeting ESMO's submission requirements [1] - The company will also showcase preliminary data from approximately 70 patients with advanced solid tumors for CS2009 in a poster presentation at the ESMO conference, marking the first known clinical data globally for a PD-1/VEGF/CTLA-4 tri-specific antibody [1] Group 2: Upcoming Events - The 2025 European Society for Medical Oncology (ESMO) annual meeting is scheduled to take place from October 17 to 21, 2025, in Berlin, Germany [1]
基石药业-B涨超3% 将于ESMO大会上公布PD-1/VEGF/CTLA-4三抗I期剂量递增临床数据